Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06939803 · ClinicalTrials.gov registry record · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
A NA study of Venothromboembolism, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 2,236
- Enrollment target
- 1
- Study location
NCT06939803 is a NA study of Venothromboembolism that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 2,236 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06939803, a NA study of Venothromboembolism, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,236 participants
- Enrollment target
- 1
- Study location
Study Summary
Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses. HA-VTE is the second leading cause of long-term disability and causes significant health issues and deaths in both adults and children. About 1 in 3 people who get blood clots experience long-term complications. Reducing HA-VTE is a major challenge. This study will test a new AI method to predict and prevent HA-VTE. The goal is to see if this AI tool can reduce the number of HA-VTE cases in the Vanderbilt Health System, which includes both urban and rural hospitals. The AI tool, called VTE-AI, calculates a risk score without needing input from doctors. It will suggest reconsidering blood clot prevention measures for patients who don't have them ordered and have no reasons to avoid them. This suggestion will be made after admission and daily during the hospital stay. Currently, doctors manually calculate a risk score and choose a prevention option. This study will compare the effectiveness of the AI tool against the current manual method in reducing HA-VTE cases. The study will randomly assign half of the patients to use the AI tool and the other half to the standard manual method.
Conditions Studied
Interventions
- OTHER Risk model-driven CDS
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,236 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06939803
The ClinicalTrials.gov registry entry for NCT06939803 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venothromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Risk model-driven CDS is the first listed.
NCT06939803 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06939803 about?
NCT06939803 is a clinical study titled "AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.". Hospital-acquired blood clots (HA-VTE) are the leading cause of death in hospitalized patients in the US. Each year, about 900,000 people get blood clots, costing between $7 and $10 billion in medical expenses. HA-VTE is the second leading cause of long-term disability and causes significant health ...
What is the current status of trial NCT06939803?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,236 participants. The study started on 2025-12-17. Estimated completion is 2027-03-31.
What conditions does trial NCT06939803 study?
This clinical trial studies the following conditions: Venothromboembolism.
What interventions are being tested in trial NCT06939803?
The interventions under investigation include: Risk model-driven CDS (OTHER).
Who is sponsoring clinical trial NCT06939803?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06939803 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.